OTTAWA, Feb. 23 /CNW/ - Researchers affiliated with the University of
Ottawa's Faculty of Medicine, the Ottawa Hospital Research Institute
(OHRI), the University of Ottawa Heart Institute (UOHI) and the CHEO
Research Institute (CHEO RI) are about to embark on exciting new
research projects that could lead to better therapies for cancer,
diabetes, heart disease and other medical conditions.
The projects have been funded by the Canadian Institutes of Health
Research (CIHR) through the agency's most recent operating grant
competition. A total of 33 research teams from the Faculty of Medicine
and affiliated hospital-based research institutes have been awarded
grants worth nearly $20M in the competition. Such success highlights
both the high level of research intensity at uOttawa's Faculty of
Medicine and our institution's leading position nationally.
Some of the projects being funded:
Dr. Ilias Cagiannos, Prof. Dean Fergusson and Dr. Rodney Breau (OHRI and
uOttawa) will lead a clinical trial to determine if cooling the kidney
area during the surgical removal of kidney tumours can improve the
recovery of kidney function and reduce complications.
Dr. Darryl Davis (UOHI and uOttawa) will explore novel strategies to
enhance the regenerative capacity and retention of cardiac progenitor
Prof. Andrew Makrigiannis (uOttawa) will investigate how the immune
system recognizes unhealthy cells that need to be destroyed. In
particular, he will study how natural killer cells spot the Ly49 MHC
protein receptor, a marker of cellular health that is lost when cells
become cancerous or infected by viruses.
Prof. Robert Screaton (CHEO RI and uOttawa) will investigate a gene
called Lkb1, which plays an important role in regulating insulin
production in the pancreas. His research could lead to novel approaches
for the prevention and treatment of diabetes, which occurs when the
pancreas doesn't produce enough insulin.
Dr. Rhian Touyz (OHRI and uOttawa) will study how metabolic byproducts
called free radicals possibly contribute to high blood pressure, kidney
disease and cardiovascular problems. In particular, she will
investigate how "Nox" proteins give rise to free radicals and how they
can be harnessed for new therapies.
Prof. Barbara Vanderhyden (uOttawa and OHRI) will study the development
of ovarian cancer and the role of reproductive factors, such as
estrogen, in this process. A second project led by Dr. Vanderhyden will
look at stem cells in the ovary and how they might contribute to
Full descriptions of the CIHR's 2011 Decisions and Funded Projects are available at www.cihr.ca/e/43046.html.
The Faculty of Medicine at the University of Ottawa and its affiliated
hospital-based research institutes (Children's Hospital of Eastern
Ontario Research Institute, Élisabeth-Bruyère Research Institute,
Institut de recherche de l'Hôpital Montfort, Ottawa Hospital Research
Institute, University of Ottawa Heart Institute and University of
Ottawa Mental Health Research Institute), have a long history of
conducting both basic and clinical research of the highest quality. The
work performed by these institutions not only leads to biomedical
discoveries that have a significant impact on the health of Canadians,
but also trains the next generation of Canadian scientists.
SOURCE UNIVERSITY OF OTTAWA
For further information:
Karine Proulx, University of Ottawa, 613- 562-5800, ext. 3149, cell 613-219-3058, firstname.lastname@example.org
Jennifer Paterson, OHRI, 613-798-5555, ext. 73325, email@example.com
Marlene Orton, UOHI, 613-761-4427, cell 613-899-6760, firstname.lastname@example.org
Isabelle Mailloux, CHEO RI, 613-737-7600, ext. 3536, IMailloux@cheo.on.ca
David Coulombe, CIHR, 613-941-4563, David.Coulombe@irsc-cihr.gc.ca